Cargando…

Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy

Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness and rapid eye movement sleep dysregulation, manifesting as cataplexy and sleep paralysis, as well as hypnagogic and hypnopompic hallucinations. Disease onset may occur at any age, although adolescents and young adults...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romigi, Andrea, Vitrani, Giuseppe, Lo Giudice, Temistocle, Centonze, Diego, Franco, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124464/ https://www.ncbi.nlm.nih.gov/pubmed/30214155 http://dx.doi.org/10.2147/DDDT.S101145

Ejemplares similares

Update on the treatment of narcolepsy: clinical efficacy of pitolisant
por: Calik, Michael W
Publicado: (2017)

Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review
por: Fabara, Stephanie P, et al.
Publicado: (2021)

Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort
por: Mutti, Carlotta, et al.
Publicado: (2022)

Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report
por: Pellitteri, Gaia, et al.
Publicado: (2020)

Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach
por: Lehert, Philippe, et al.
Publicado: (2020)

Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study
por: Dauvilliers, Yves, et al.
Publicado: (2019)

Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility
por: Guevarra, Jay T, et al.
Publicado: (2020)

Zonisamide in the management of epilepsy in the elderly
por: Romigi, Andrea, et al.
Publicado: (2015)

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
por: Meskill, Gerard J., et al.
Publicado: (2021)

Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
por: Watson, Nathaniel F., et al.
Publicado: (2021)

Evaluation of the abuse potential of pitolisant, a selective H(3)-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
por: Setnik, Beatrice, et al.
Publicado: (2019)

Topiramate-induced periodic limb movement disorder in a patient affected by focal epilepsy
por: Romigi, Andrea, et al.
Publicado: (2014)

Oral L-carnitine and pregnancy: real opportunity for narcoleptic women?
por: Romigi, Andrea, et al.
Publicado: (2019)

Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update
por: Romigi, Andrea, et al.
Publicado: (2022)

Treat the Symptom, Not the Cause? Pitolisant for Sleepiness in Obstructive Sleep Apnea
por: Trotti, Lynn Marie
Publicado: (2020)

Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects
por: Harwell, Victoria, et al.
Publicado: (2020)

New developments in the management of narcolepsy
por: Abad, Vivien C, et al.
Publicado: (2017)

Narcolepsy
por: Maclachlan, T. Kay
Publicado: (1930)

Narcolepsy
Publicado: (1929)

The histamine H(3) receptor inverse agonist pitolisant reduces body weight in obese mice
por: Kotańska, Magdalena, et al.
Publicado: (2018)

A practical guide to the pharmacological and behavioral therapy of Narcolepsy
por: Franceschini, Christian, et al.
Publicado: (2021)

Diagnosis and management of narcolepsy in the Indian scenario
por: Sureshbabu, Sachin, et al.
Publicado: (2016)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
por: Gomez-Peralta, Fernando, et al.
Publicado: (2019)

H(3) histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice
por: Dudek, Magdalena, et al.
Publicado: (2016)

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol
por: Krief, Stéphane, et al.
Publicado: (2021)

Intellectual Abilities of Children with Narcolepsy
por: Thieux, Marine, et al.
Publicado: (2020)

Misdiagnosis of narcolepsy
por: Dunne, Laura, et al.
Publicado: (2016)

Idiopathic Narcolepsy
Publicado: (1927)

Genetics of narcolepsy
por: Miyagawa, Taku, et al.
Publicado: (2019)

Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy
por: Dauvilliers, Yves, et al.
Publicado: (2012)

Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning
por: Zhang, Zhongxing, et al.
Publicado: (2018)

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
por: Tatenuma, Tomoyuki, et al.
Publicado: (2023)

Meditation-Relaxation (MR Therapy) for Sleep Paralysis: A Pilot Study in Patients With Narcolepsy
por: Jalal, Baland, et al.
Publicado: (2020)

Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy
por: Ollila, Hanna M., et al.
Publicado: (2023)

Impact of COVID‐19 pandemic lockdown on narcolepsy type 1 management
por: Postiglione, Emanuela, et al.
Publicado: (2020)

Narcolepsy: a review
por: Akintomide, Gbolagade Sunmaila, et al.
Publicado: (2011)

A Case of Narcolepsy
por: Rogers, Bertram M. H.
Publicado: (1907)

Narcolepsy type 1
por: Swarnakar, Rajesh, et al.
Publicado: (2019)

A Case of Narcolepsy
por: Rogers, Bertram M. H.
Publicado: (1907)

Multidisciplinary care of patients with narcolepsy during coronavirus disease 2019 pandemic in Italy via televisit: the TElemedicine for NARcolepsy feasibility study
por: Pizza, Fabio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e85hb7n20qll1kknt842nb2e1i